Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Angi Inc (ANGI) Price & Performance

ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.

ANGI trades at $4.41, down 3.92% with bearish technical signals and mixed fundamentals. Revenue declined to $1.03B in 2025, though net income improved to $44M. The stock appears undervalued with P/E of 14.81 and P/S of 0.19, but faces challenges with declining revenue trends and negative 2026 projections. Recent Q2 2026 earnings missed expectations with a $5.70 EPS loss versus $0.13 expected, while multiple law firms investigate potential securities violations.

Outlook remains challenging with revenue projected to decline to $993M in 2026 and net loss of $222M. The 59% upside to consensus price target of $7.00 offers potential reward, but risks include accelerating pro user churn, negative cash flow trends, and ongoing securities investigations. Analyst sentiment is cautious with 64% hold ratings amid fundamental deterioration.